1 recruiting, 1 terminated, 1 unknown. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
Follow FOLFIRI Protocol: new trials by email Literature Review of FOLFIRI Protocol trials Research Report on FOLFIRI Protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NEO212 Oral Capsule, Ipilimumab, Pembrolizumab - Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype | Phase 1 / Phase 2 | Recruiting | Neonc Technologies, Inc. | 134 | 2023-11-01 | 2026-09-24 |
| A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors SM08502, Abiraterone, Prednisone - Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer | Phase 1 | Terminated | Biosplice Therapeutics, Inc. | 30 | 2021-11-03 | 2024-08-09 |
| A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI FOLFIRI Protocol, SCO-101 - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Unknown | Scandion Oncology A/S | 35 | 2020-05-14 | 2022-03-02 |
Colorectal Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Central Nervous System Neoplasms (1) · Esophageal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Glioblastoma (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1)
Biosplice Therapeutics, Inc. (1) · Neonc Technologies, Inc. (1) · Scandion Oncology A/S (1)
United States (2) · Australia (1) · Denmark (1) · Germany (1) · Spain (1)
Darrin Beaupre, MD, PhD, CMO (1) · Jacob Hagen Vasehus Schou, MD (1) · Josh Neman, PhD (1) · Tom Chen, MD, PhD (1)